HomeCompareALVR vs YUM

ALVR vs YUM: Dividend Comparison 2026

ALVR yields 20.39% · YUM yields 1.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YUM wins by $32.2K in total portfolio value· pulled ahead in Year 10
10 years
ALVR
ALVR
● Live price
20.39%
Share price
$9.81
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$74.8K
Annual income
$7,021.90
Full ALVR calculator →
YUM
YUM
● Live price
1.85%
Share price
$155.48
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.0K
Annual income
$39,957.33
Full YUM calculator →

Portfolio growth — ALVR vs YUM

📍 YUM pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALVRYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALVR + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALVR pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALVR
Annual income on $10K today (after 15% tax)
$1,732.93/yr
After 10yr DRIP, annual income (after tax)
$5,968.62/yr
YUM
Annual income on $10K today (after 15% tax)
$157.45/yr
After 10yr DRIP, annual income (after tax)
$33,963.73/yr
At 15% tax rate, YUM beats the other by $27,995.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALVR + YUM for your $10,000?

ALVR: 50%YUM: 50%
100% YUM50/50100% ALVR
Portfolio after 10yr
$90.9K
Annual income
$23,489.61/yr
Blended yield
25.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

ALVR
Analyst Ratings
4
Buy
2
Hold
2
Sell
Consensus: Buy
Altman Z
-1.3
Piotroski
1/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+11.4% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALVR buys
0
YUM buys
0
No recent congressional trades found for ALVR or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALVRYUM
Forward yield20.39%1.85%
Annual dividend / share$2.00$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$74.8K$107.0K
Annual income after 10y$7,021.90$39,957.33
Total dividends collected$42.9K$80.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyHold

Year-by-year: ALVR vs YUM ($10,000, DRIP)

YearALVR PortfolioALVR Income/yrYUM PortfolioYUM Income/yrGap
1$12,739$2,038.74$10,980$280.44+$1.8KALVR
2$16,058$2,427.19$12,185$435.72+$3.9KALVR
3$20,041$2,859.40$13,722$684.14+$6.3KALVR
4$24,779$3,335.27$15,773$1,090.14+$9.0KALVR
5$30,368$3,854.01$18,650$1,773.02+$11.7KALVR
6$36,908$4,414.23$22,921$2,966.37+$14.0KALVR
7$44,505$5,013.90$29,685$5,158.69+$14.8KALVR
8$53,271$5,650.48$41,216$9,453.02+$12.1KALVR
9$63,321$6,320.94$62,672$18,571.31+$649.00ALVR
10← crossover$74,775$7,021.90$107,016$39,957.33$32.2KYUM

ALVR vs YUM: Complete Analysis 2026

ALVRStock

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Full ALVR Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this ALVR vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALVR vs SCHDALVR vs JEPIALVR vs OALVR vs KOALVR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.